Related Experiment Videos
STAT signaling in the pathogenesis and treatment of cancer
1Department of Adult Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts 02115, USA. david_frank@dfci.harvard.edu
Abstract:
Exceptional advances have been made recently in our understanding of the signaling pathways that control cellular growth, differentiation, and survival. These processes are regulated by extracellular stimuli such as cytokines, cell-cell interactions, and cell-matrix interactions, which trigger a series of intracellular events culminating in the modulation of specific genes. STATs are a highly homologous group of transcription factors that are activated by various pathways and regulate many of the genes controlling cellular function. STATs are activated by tyrosine phosphorylation and modulated by serine phosphorylation, placing them at a convergence point for numerous intracellular signaling pathways. Given the importance of STATs in the control of normal physiologic processes, it is not surprising that inappropriate activation of these proteins has been found in human malignancies. A number of distinct mechanisms have been elucidated by which STATs are activated inappropriately, including autocrine or paracrine stimulation of normal receptors and increased activity of tyrosine kinases through enhanced expression, mutations, or the presence of activating proteins. Furthermore, inappropriate STAT serine phosphorylation has been found in several tumors as well. The increased understanding of signaling pathways in tumors can be translated into therapeutic strategies that have the potential to be more selective and less toxic than current anti-cancer treatments. Approaches which may be effective include the development of antagonists of receptors that can trigger STAT activation, inhibitors of the tyrosine and serine kinases that phosphorylate and activate STATs, agents that decrease STAT levels or inhibit their recruitment to kinases, and molecules that can prevent the binding of STATs to target DNA sequences. Thus, elucidation of cellular and biochemical processes in tumors has enhanced our understanding of the pathogenesis of malignancies and may provide the basis for significant advances in therapy.
Insights
Signal transducer and activator of transcription (STAT) proteins regulate cellular functions but are inappropriately activated in cancers. Understanding these pathways offers new therapeutic strategies for malignancies.
Area of Science:
- Molecular Biology
- Cell Biology
- Cancer Biology
Background:
- Cellular growth, differentiation, and survival are controlled by complex signaling pathways.
- Signal transducer and activator of transcription (STAT) proteins are key transcription factors regulated by these pathways.
- Aberrant STAT activation is implicated in the development of human malignancies.
Purpose of the Study:
- To review the role of STATs in cellular processes and their dysregulation in cancer.
- To explore the mechanisms of inappropriate STAT activation in tumors.
- To discuss potential therapeutic strategies targeting STAT signaling in cancer treatment.
Main Methods:
- Literature review of signaling pathways and STAT protein function.
- Analysis of mechanisms leading to STAT dysregulation in malignancies.
- Identification of potential therapeutic targets within the STAT signaling cascade.
Main Results:
- STATs are activated by tyrosine and serine phosphorylation, converging multiple signaling pathways.
- Inappropriate STAT activation in cancer can result from autocrine/paracrine receptor stimulation or increased tyrosine kinase activity.
- Dysregulated STAT serine phosphorylation is also observed in several tumors.
Conclusions:
- Understanding STAT signaling in cancer pathogenesis provides a basis for novel therapeutic approaches.
- Targeting STAT activation pathways, including receptor antagonists and kinase inhibitors, may lead to more selective and less toxic anti-cancer treatments.
- Elucidation of these cellular and biochemical processes enhances cancer therapy development.